These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36854526)

  • 21. Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review.
    Giudici N; Bonne F; Blarer J; Minoli M; Krentel F; Seiler R
    Transl Androl Urol; 2021 Oct; 10(10):4036-4050. PubMed ID: 34804846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
    Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
    Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
    Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
    Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
    Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA Hypomethylation Is Associated with the Overexpression of INHBA in Upper Tract Urothelial Carcinoma.
    Kao CC; Chang YL; Liu HY; Wu ST; Meng E; Cha TL; Sun GH; Yu DS; Luo HL
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression.
    Zuo W; Wang ZZ; Xue J
    Int J Mol Sci; 2014 Aug; 15(8):14298-312. PubMed ID: 25196524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
    Minato A; Fujimoto N; Kubo T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1063-e1067. PubMed ID: 28803791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
    Yates DR; Catto JW
    World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
    Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study.
    Kuo KL; Liu SH; Lin WC; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
    Cells; 2019 Oct; 8(10):. PubMed ID: 31627336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent.
    Ojha R; Singh SK; Bhattacharyya S; Dhanda RS; Rakha A; Mandal AK; Jha V
    J Urol; 2014 Jun; 191(6):1889-98. PubMed ID: 24440234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ganoderma microsporum immunomodulatory protein induces apoptosis and potentiates mitomycin C-induced apoptosis in urinary bladder urothelial carcinoma cells.
    Huang SY; Chien CC; Hseu RS; Huang VYJ; Chiang SY; Huang CJ; Chen SK; Tsai RY; Lin HT; Cheng YC
    J Cell Biochem; 2018 Jun; 119(6):4592-4606. PubMed ID: 29240252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
    Saito K; Urakami S; Komai Y; Yasuda Y; Kubo Y; Kitsukawa S; Okubo Y; Yamamoto S; Yonese J; Fukui I
    BJU Int; 2012 Nov; 110(10):1478-84. PubMed ID: 22520732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
    J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhibiting MAPK pathway.
    Li W; Ma G; Deng Y; Wu Q; Wang Z; Zhou Q
    Gene; 2021 Jan; 766():145134. PubMed ID: 32898605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells.
    Zhou X; Chen Y; Wang F; Wu H; Zhang Y; Liu J; Cai Y; Huang S; He N; Hu Z; Jin X
    Chem Biol Interact; 2020 Nov; 331():109273. PubMed ID: 33002460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
    Wu K; Liu X; Wang Y; Wang X; Li X
    Front Public Health; 2022; 10():994351. PubMed ID: 36388369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.
    Shang D; Liu Y; Matsui Y; Ito N; Nishiyama H; Kamoto T; Ogawa O
    Urology; 2008 Jun; 71(6):1220-5. PubMed ID: 18538698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    D'Andrea D; Matin S; Black PC; Petros FG; Zargar H; Dinney CP; Cookson MS; Kassouf W; Dall'Era MA; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; Sridhar SS; North S; Barocas DA; Lotan Y; Stephenson AJ; van Rhijn BW; Spiess PE; Daneshmand S; Shariat SF
    BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.